SCHEMBL4205124

SCHEMBL4205124

COC(=O)c1cc(Cc2cccc(Cl)c2F)c(OC)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 1/20 0.48
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.44
PLA2G2A P14555 1/20 0.43
LMNA P02545 4/20 0.42
HPGD P15428 3/20 0.42
SCN9A Q15858 1/20 0.40
CSF1R P07333 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 1/20 0.40
GAA P10253 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209881 0.92 METTL3 (0.48) METTL3PDE3BPDE3AMRGPRX4PLA2G2A
SCHEMBL4214457 0.90 METTL3 (0.46) METTL3PDE3BPDE3AMRGPRX4LMNA
SCHEMBL4199027 0.89 METTL3 (0.48) METTL3PDE3BPDE3ALMNASCN9A
SCHEMBL4210123 0.89 METTL3 (0.55) METTL3MRGPRX4LMNASCN9ACSF1R
SCHEMBL13927523 0.89 METTL3 (0.48) METTL3PDE3BPDE3ALMNAHPGD
SCHEMBL13927572 0.88 PDE3B (0.48) METTL3PDE3BPDE3AMRGPRX4PLA2G2A
SCHEMBL13927525 0.87 METTL3 (0.46) METTL3PDE3BPDE3AMRGPRX4LMNA
SCHEMBL13927547 0.84 METTL3 (0.47) METTL3PDE3BPDE3ALMNASCN9A
SCHEMBL4207612 0.84 METTL3 (0.50) METTL3PDE3BPDE3AMRGPRX4LMNA
SCHEMBL4211543 0.84 METTL3 (0.43) METTL3PDE3BPDE3AMRGPRX4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound JAPAN TOBACCO INC. (JP) 2018-09-20 US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 US disclosed
EP-1992607-B9 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-07-01 EP disclosed
EP-1992607-B9 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-07-01 EP disclosed
EP-1992607-B1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2014-12-31 EP disclosed
EP-1992607-B1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2014-12-31 EP disclosed
US-20130310595-A1 Method for Producing 4-Oxoquinoline Compound JAPAN TOBACCO INC. (JP) 2013-11-21 US disclosed
US-20130310595-A1 Method for Producing 4-Oxoquinoline Compound JAPAN TOBACCO INC. (JP) 2013-11-21 US disclosed
CN-101437785-B Process for preparing 4-oxoquinoline compounds JAPAN TOBACCO INC 2013-05-29 CN disclosed
US-8383819-B2 Method for producing 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2013-02-26 US disclosed
US-8383819-B2 Method for producing 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2013-02-26 US disclosed
US-8383819-B2 Method for producing 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2013-02-26 US disclosed
US-20090182140-A1 Alicyclic Heterocyclic Compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-07-16 US disclosed
CN-101437785-A Process for preparing 4-oxoquinoline compounds JAPAN TOBACCO INC (JP) 2009-05-20 CN disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
EP-1992607-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2008-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 METTL3 938/4885PDE3B 1957/4885PDE3A 2028/4885
US-20090182140-A1 Alicyclic Heterocyclic Compound CCR4, CCR1, HRH4 METTL3 4404/4885PDE3B 2093/4885PDE3A 2863/4885
US-20130310595-A1 Method for Producing 4-Oxoquinoline Compound IMPDH1, IMPDH2, CDK20 METTL3 938/4885PDE3B 1957/4885PDE3A 2028/4885
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound IMPDH1, IMPDH2, CDK20 METTL3 938/4885PDE3B 1957/4885PDE3A 2028/4885
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 METTL3 938/4885PDE3B 1957/4885PDE3A 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.